Free Trial

Fulgent Genetics (FLGT) Financials

Fulgent Genetics logo
$19.04 +0.14 (+0.74%)
As of 04/24/2025 04:00 PM Eastern
Annual Income Statements for Fulgent Genetics

Annual Income Statements for Fulgent Genetics

This table shows Fulgent Genetics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders
143 -168 -43
Consolidated Net Income / (Loss)
142 -175 -44
Net Income / (Loss) Continuing Operations
142 -175 -44
Total Pre-Tax Income
184 -174 -52
Total Operating Income
179 -196 -74
Total Gross Profit
367 104 107
Total Revenue
619 289 283
Operating Revenue
619 289 283
Total Cost of Revenue
252 185 176
Operating Cost of Revenue
252 185 176
Total Operating Expenses
188 300 181
Selling, General & Admin Expense
111 89 88
Marketing Expense
39 41 36
Research & Development Expense
29 41 49
Amortization Expense
6.50 7.85 7.97
Impairment Charge
0.00 120 0.00
Restructuring Charge
2.98 0.00 0.00
Total Other Income / (Expense), net
5.50 21 22
Interest Expense
- - -0.17
Interest & Investment Income
5.62 22 31
Other Income / (Expense), net
0.89 0.32 -9.51
Income Tax Expense
42 1.15 -8.14
Net Income / (Loss) Attributable to Noncontrolling Interest
-1.48 -7.41 -1.11
Weighted Average Basic Shares Outstanding
30.10M 29.78M 30.24M
Weighted Average Diluted Shares Outstanding
30.96M 29.78M 30.24M
Weighted Average Basic & Diluted Shares Outstanding
29.52M 29.78M 30.83M

Quarterly Income Statements for Fulgent Genetics

This table shows Fulgent Genetics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders
1.72 -24 -15 -11 -13 -128 -13 -8.71 -15 -5.89
Consolidated Net Income / (Loss)
1.34 -24 -16 -12 -13 -134 -14 -9.09 -15 -6.19
Net Income / (Loss) Continuing Operations
1.34 -24 -16 -12 -13 -134 -14 -9.09 -15 -6.19
Total Pre-Tax Income
1.76 -33 -21 -15 6.86 -145 -14 -11 -19 -8.04
Total Operating Income
0.35 -37 -25 -20 0.21 -151 -22 -19 -17 -16
Total Gross Profit
46 13 19 21 40 25 22 26 27 32
Total Revenue
106 68 66 68 85 71 64 71 72 76
Operating Revenue
106 68 66 68 85 71 64 71 72 76
Total Cost of Revenue
60 55 47 47 45 45 42 45 45 44
Operating Cost of Revenue
60 55 47 47 45 45 42 45 45 44
Total Operating Expenses
46 50 44 40 40 176 44 45 44 48
Selling, General & Admin Expense
26 29 22 18 17 32 21 21 21 24
Marketing Expense
9.86 10 10 11 10 11 8.99 8.60 9.12 9.54
Research & Development Expense
7.51 8.51 9.78 9.69 10 12 11 13 12 12
Amortization Expense
2.01 2.01 1.97 1.96 1.96 1.96 1.99 1.99 1.99 1.99
Total Other Income / (Expense), net
1.41 3.09 3.78 5.10 6.65 5.93 7.63 7.69 -1.45 8.10
Interest & Investment Income
1.41 3.22 3.78 5.10 6.47 6.27 7.63 7.69 8.09 7.90
Income Tax Expense
0.41 -9.39 -5.20 -3.11 20 -11 -0.33 -2.12 -3.84 -1.85
Net Income / (Loss) Attributable to Noncontrolling Interest
-0.38 -0.24 -0.51 -0.36 -0.36 -6.19 -0.38 -0.38 -0.05 -0.30
Weighted Average Basic Shares Outstanding
30.17M 30.10M 29.54M 29.81M 30.01M 29.78M 29.77M 30.10M 30.42M 30.24M
Weighted Average Diluted Shares Outstanding
30.87M 30.96M 29.54M 29.81M 30.01M 29.78M 29.77M 30.10M 30.42M 30.24M
Weighted Average Basic & Diluted Shares Outstanding
29.44M 29.52M 29.70M 29.93M 29.63M 29.78M 29.92M 30.30M 30.59M 30.83M

Annual Cash Flow Statements for Fulgent Genetics

This table details how cash moves in and out of Fulgent Genetics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Change in Cash & Equivalents
-85 18 -42
Net Cash From Operating Activities
254 27 21
Net Cash From Continuing Operating Activities
254 27 21
Net Income / (Loss) Continuing Operations
142 -175 -44
Consolidated Net Income / (Loss)
142 -175 -44
Depreciation Expense
33 26 25
Amortization Expense
4.77 -3.91 -5.55
Non-Cash Adjustments To Reconcile Net Income
60 177 61
Changes in Operating Assets and Liabilities, net
14 2.82 -15
Net Cash From Investing Activities
-261 39 -58
Net Cash From Continuing Investing Activities
-261 39 -58
Purchase of Property, Plant & Equipment
-19 -22 -40
Acquisitions
-183 -0.40 0.00
Purchase of Investments
-418 -492 -472
Sale of Property, Plant & Equipment
0.41 0.78 0.31
Sale and/or Maturity of Investments
373 553 454
Other Investing Activities, net
-15 0.00 0.00
Net Cash From Financing Activities
-77 -48 -4.85
Net Cash From Continuing Financing Activities
-77 -48 -4.85
Repayment of Debt
-0.37 -4.27 -1.23
Repurchase of Common Equity
-74 -25 -0.23
Other Financing Activities, net
-2.44 -18 -3.39
Effect of Exchange Rate Changes
-0.45 -0.15 -0.06
Cash Interest Paid
0.00 0.96 0.51
Cash Income Taxes Paid
56 3.26 28

Quarterly Cash Flow Statements for Fulgent Genetics

This table details how cash moves in and out of Fulgent Genetics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents
30 -89 -13 -7.82 26 13 -43 10 -6.93 -2.90
Net Cash From Operating Activities
21 33 -7.91 9.74 10 15 7.27 4.29 -16 25
Net Cash From Continuing Operating Activities
21 33 -7.91 9.74 10 15 7.27 4.29 -16 25
Net Income / (Loss) Continuing Operations
1.34 -24 -16 -12 -13 -134 -14 -9.09 -15 -6.19
Consolidated Net Income / (Loss)
1.34 -24 -16 -12 -13 -134 -14 -9.09 -15 -6.19
Depreciation Expense
9.82 9.80 6.88 6.31 6.42 6.53 6.66 6.15 5.92 6.19
Amortization Expense
1.01 0.54 -0.48 -0.71 -1.19 -1.53 -1.18 -1.49 -1.34 -1.55
Non-Cash Adjustments To Reconcile Net Income
17 6.87 10 15 6.67 145 9.77 17 19 15
Changes in Operating Assets and Liabilities, net
-8.58 40 -8.47 0.24 12 -0.76 5.86 -8.16 -25 12
Net Cash From Investing Activities
44 -93 -4.35 -1.10 20 24 -47 7.30 8.99 -27
Net Cash From Continuing Investing Activities
44 -93 -4.35 -1.10 20 24 -47 7.30 8.99 -27
Purchase of Property, Plant & Equipment
-5.44 -4.72 -2.03 -12 -4.92 -3.11 -4.06 -13 -20 -3.78
Purchase of Investments
-12 -146 -144 -107 -93 -148 -196 -63 -115 -98
Sale and/or Maturity of Investments
61 108 141 117 118 176 152 83 144 75
Net Cash From Financing Activities
-35 -30 -1.10 -16 -4.47 -26 -2.81 -1.15 -0.57 -0.33
Net Cash From Continuing Financing Activities
-35 -30 -1.10 -16 -4.47 -26 -2.81 -1.15 -0.57 -0.33
Other Financing Activities, net
-0.76 -0.54 -1.10 -15 14 -16 -1.82 -0.68 -0.57 -0.33
Effect of Exchange Rate Changes
0.39 -0.28 0.03 -0.21 -0.12 0.15 -0.07 -0.01 0.16 -0.13
Cash Interest Paid
- - 0.00 0.92 0.02 0.02 0.44 0.01 0.01 0.05
Cash Income Taxes Paid
1.20 0.01 1.68 0.96 0.06 0.56 1.31 0.60 25 0.95

Annual Balance Sheets for Fulgent Genetics

This table presents Fulgent Genetics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Total Assets
1,386 1,235 1,220
Total Current Assets
628 508 354
Cash & Equivalents
80 97 55
Short-Term Investments
447 327 203
Accounts Receivable
53 51 69
Other Current Assets
49 33 26
Plant, Property, & Equipment, net
81 83 106
Total Noncurrent Assets
677 644 761
Long-Term Investments
339 444 570
Goodwill
143 22 22
Intangible Assets
151 143 135
Other Noncurrent Operating Assets
44 35 33
Total Liabilities & Shareholders' Equity
1,386 1,235 1,220
Total Liabilities
116 102 91
Total Current Liabilities
88 73 73
Short-Term Debt
21 1.18 0.41
Accounts Payable
23 15 18
Accrued Expenses
25 31 24
Customer Deposits
11 23 28
Current Deferred Revenue
3.20 2.87 2.23
Other Current Liabilities
5.30 0.16 0.00
Total Noncurrent Liabilities
28 29 18
Noncurrent Deferred & Payable Income Tax Liabilities
9.84 14 11
Other Noncurrent Operating Liabilities
18 15 6.97
Commitments & Contingencies
0.00 0.00 0.00
Total Equity & Noncontrolling Interests
1,270 1,133 1,129
Total Preferred & Common Equity
1,267 1,136 1,133
Preferred Stock
0.00 0.00 0.00
Total Common Equity
1,267 1,136 1,133
Common Stock
487 502 543
Retained Earnings
801 633 590
Accumulated Other Comprehensive Income / (Loss)
-21 1.21 -0.37
Noncontrolling Interest
3.19 -2.82 -4.07

Quarterly Balance Sheets for Fulgent Genetics

This table presents Fulgent Genetics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets
1,406 1,377 1,355 1,358 1,230 1,232 1,234
Total Current Assets
697 581 528 550 387 399 327
Cash & Equivalents
169 66 58 84 55 65 58
Short-Term Investments
402 438 400 384 251 247 155
Accounts Receivable
104 44 35 49 52 57 57
Other Current Assets
21 33 35 33 29 31 56
Plant, Property, & Equipment, net
82 79 88 85 87 93 107
Total Noncurrent Assets
627 717 739 723 757 740 800
Long-Term Investments
358 380 401 399 561 547 602
Goodwill
120 143 142 142 22 22 22
Intangible Assets
88 149 146 144 141 139 137
Other Noncurrent Operating Assets
61 45 49 38 33 32 39
Total Liabilities & Shareholders' Equity
1,406 1,377 1,355 1,358 1,230 1,232 1,234
Total Liabilities
124 108 91 97 103 103 99
Total Current Liabilities
103 82 65 61 76 76 74
Short-Term Debt
20 5.61 4.56 2.89 0.41 0.41 0.41
Accounts Payable
14 22 21 16 20 20 20
Accrued Expenses
25 21 22 21 26 26 24
Customer Deposits
26 12 14 19 27 26 27
Current Deferred Revenue
2.60 2.73 2.60 2.59 2.76 2.74 2.97
Other Current Liabilities
14 19 0.36 0.28 0.00 0.00 0.00
Total Noncurrent Liabilities
22 26 26 35 27 28 25
Noncurrent Deferred & Payable Income Tax Liabilities
1.83 9.84 9.84 19 13 13 13
Other Noncurrent Operating Liabilities
20 16 17 16 14 14 12
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
1,281 1,269 1,263 1,262 1,127 1,129 1,135
Total Preferred & Common Equity
1,277 1,264 1,260 1,259 1,130 1,133 1,138
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
1,277 1,264 1,260 1,259 1,130 1,133 1,138
Common Stock
478 496 506 514 511 522 533
Retained Earnings
825 786 774 761 620 611 596
Accumulated Other Comprehensive Income / (Loss)
-26 -17 -21 -17 -1.10 -0.88 9.18
Noncontrolling Interest
4.35 4.47 3.56 3.14 -3.30 -3.70 -3.55

Annual Metrics and Ratios for Fulgent Genetics

This table displays calculated financial ratios and metrics derived from Fulgent Genetics' official financial filings.

Metric 2022 2023 2024
Growth Metrics
- - -
Revenue Growth
-37.64% -53.28% -1.99%
EBITDA Growth
-68.78% -179.77% 62.97%
EBIT Growth
-73.46% -208.80% 57.26%
NOPAT Growth
-72.55% -199.41% 62.20%
Net Income Growth
-71.97% -223.47% 74.99%
EPS Growth
0.00% 0.00% 0.00%
Operating Cash Flow Growth
-52.93% -89.35% -22.01%
Free Cash Flow Firm Growth
-111.56% 146.06% -492.19%
Invested Capital Growth
77.44% -37.38% 13.07%
Revenue Q/Q Growth
-22.91% 0.98% 2.06%
EBITDA Q/Q Growth
-45.60% -223.97% 66.14%
EBIT Q/Q Growth
-50.97% -141.12% 60.06%
NOPAT Q/Q Growth
-48.61% -141.51% 64.62%
Net Income Q/Q Growth
-47.37% -169.68% 74.52%
EPS Q/Q Growth
0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth
-14.75% -40.36% 91.89%
Free Cash Flow Firm Q/Q Growth
-198.91% 126.87% -27.02%
Invested Capital Q/Q Growth
14.12% -33.11% -5.90%
Profitability Metrics
- - -
Gross Margin
59.28% 36.12% 37.82%
EBITDA Margin
35.03% -59.81% -22.60%
Operating Margin
28.84% -67.61% -26.08%
EBIT Margin
28.99% -67.50% -29.43%
Profit (Net Income) Margin
22.93% -60.59% -15.46%
Tax Burden Percent
77.12% 100.66% 84.34%
Interest Burden Percent
102.57% 89.18% 62.28%
Effective Tax Rate
22.88% 0.00% 0.00%
Return on Invested Capital (ROIC)
41.41% -39.58% -18.24%
ROIC Less NNEP Spread (ROIC-NNEP)
40.94% -35.10% -19.17%
Return on Net Nonoperating Assets (RNNOA)
-29.76% 25.00% 14.36%
Return on Equity (ROE)
11.65% -14.58% -3.87%
Cash Return on Invested Capital (CROIC)
-14.41% 6.38% -30.51%
Operating Return on Assets (OROA)
13.47% -14.89% -6.80%
Return on Assets (ROA)
10.65% -13.37% -3.57%
Return on Common Equity (ROCE)
11.60% -14.58% -3.89%
Return on Equity Simple (ROE_SIMPLE)
11.20% -15.42% -3.87%
Net Operating Profit after Tax (NOPAT)
138 -137 -52
NOPAT Margin
22.24% -47.33% -18.25%
Net Nonoperating Expense Percent (NNEP)
0.48% -4.48% 0.93%
Return On Investment Capital (ROIC_SIMPLE)
10.67% -12.06% -4.58%
Cost of Revenue to Revenue
40.72% 63.88% 62.18%
SG&A Expenses to Revenue
17.95% 30.77% 31.08%
R&D to Revenue
4.67% 14.33% 17.22%
Operating Expenses to Revenue
30.43% 103.72% 63.90%
Earnings before Interest and Taxes (EBIT)
179 -195 -83
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
217 -173 -64
Valuation Ratios
- - -
Price to Book Value (P/BV)
0.69 0.75 0.50
Price to Tangible Book Value (P/TBV)
0.90 0.88 0.58
Price to Revenue (P/Rev)
1.42 2.96 1.99
Price to Earnings (P/E)
6.11 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00%
Earnings Yield
16.36% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.08 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.06 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.16 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.20 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.26 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.14 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00
Leverage & Solvency
- - -
Debt to Equity
0.02 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00
Financial Leverage
-0.73 -0.71 -0.75
Leverage Ratio
1.09 1.09 1.09
Compound Leverage Factor
1.12 0.97 0.68
Debt to Total Capital
1.60% 0.10% 0.04%
Short-Term Debt to Total Capital
1.60% 0.10% 0.04%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.25% -0.25% -0.36%
Common Equity to Total Capital
98.15% 100.14% 100.32%
Debt to EBITDA
0.10 -0.01 -0.01
Net Debt to EBITDA
-3.90 5.01 12.93
Long-Term Debt to EBITDA
0.00 0.00 0.00
Debt to NOPAT
0.15 -0.01 -0.01
Net Debt to NOPAT
-6.13 6.33 16.00
Long-Term Debt to NOPAT
0.00 0.00 0.00
Altman Z-Score
6.68 5.89 4.69
Noncontrolling Interest Sharing Ratio
0.42% 0.02% -0.30%
Liquidity Ratios
- - -
Current Ratio
7.13 6.96 4.85
Quick Ratio
6.57 6.51 4.49
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
-48 22 -87
Operating Cash Flow to CapEx
1,380.60% 125.99% 52.65%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00
Efficiency Ratios
- - -
Asset Turnover
0.46 0.22 0.23
Accounts Receivable Turnover
6.46 5.57 4.72
Inventory Turnover
0.00 0.00 0.00
Fixed Asset Turnover
8.62 3.51 3.00
Accounts Payable Turnover
11.57 9.61 10.45
Days Sales Outstanding (DSO)
56.51 65.55 77.36
Days Inventory Outstanding (DIO)
0.00 0.00 0.00
Days Payable Outstanding (DPO)
31.56 37.98 34.92
Cash Conversion Cycle (CCC)
24.95 27.57 42.44
Capital & Investment Metrics
- - -
Invested Capital
425 266 301
Invested Capital Turnover
1.86 0.84 1.00
Increase / (Decrease) in Invested Capital
186 -159 35
Enterprise Value (EV)
35 -13 -267
Market Capitalization
877 857 565
Book Value per Share
$43.03 $38.34 $37.05
Tangible Book Value per Share
$33.05 $32.77 $31.92
Total Capital
1,291 1,134 1,130
Total Debt
21 1.18 0.41
Total Long-Term Debt
0.00 0.00 0.00
Net Debt
-845 -867 -828
Capital Expenditures (CapEx)
18 21 40
Debt-free, Cash-free Net Working Capital (DFCFNWC)
34 12 23
Debt-free Net Working Capital (DFNWC)
560 436 281
Net Working Capital (NWC)
540 435 281
Net Nonoperating Expense (NNE)
-4.24 38 -7.92
Net Nonoperating Obligations (NNO)
-845 -867 -828
Total Depreciation and Amortization (D&A)
37 22 19
Debt-free, Cash-free Net Working Capital to Revenue
5.52% 4.10% 8.11%
Debt-free Net Working Capital to Revenue
90.54% 150.76% 99.16%
Net Working Capital to Revenue
87.20% 150.35% 99.01%
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding
0.00 29.78M 30.24M
Adjusted Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding
0.00 29.78M 30.24M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 29.78M 30.83M
Normalized Net Operating Profit after Tax (NOPAT)
140 -53 -52
Normalized NOPAT Margin
22.61% -18.22% -18.25%
Pre Tax Income Margin
29.73% -60.19% -18.33%
Debt Service Ratios
- - -
EBIT to Interest Expense
0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00
Payout Ratios
- - -
Dividend Payout Ratio
0.00% 0.00% 0.00%
Augmented Payout Ratio
52.38% -14.30% -0.51%

Quarterly Metrics and Ratios for Fulgent Genetics

This table displays calculated financial ratios and metrics derived from Fulgent Genetics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics
- - - - - - - - - -
Revenue Growth
-53.63% -73.10% -79.34% -45.87% -19.85% 4.14% -2.54% 4.68% -15.28% 8.10%
EBITDA Growth
-93.22% -116.75% -108.83% -163.25% -49.13% -457.42% 11.42% -0.27% -487.25% 92.14%
EBIT Growth
-99.78% -124.23% -112.29% -254.74% 30.11% -313.44% 12.19% 4.51% -5,909.61% 89.32%
NOPAT Growth
-99.78% -124.67% -111.32% -234.21% -256.13% -313.44% 12.19% 4.51% -2,745.98% 89.32%
Net Income Growth
-98.90% -123.22% -110.32% -204.42% -1,102.68% -457.96% 12.64% 21.57% -9.12% 95.39%
EPS Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth
-86.35% -56.92% -104.20% -12.48% -50.71% -55.03% 191.89% -55.99% -251.46% 67.54%
Free Cash Flow Firm Growth
-533.41% -1,373.31% -634.00% 77.26% 88.19% 125.17% 162.09% 355.41% 355.50% -186.73%
Invested Capital Growth
143.34% 77.44% 74.88% 9.29% 6.83% -37.38% -33.26% -33.63% -19.62% 13.07%
Revenue Q/Q Growth
-15.71% -35.92% -2.27% 2.55% 24.81% -16.75% -8.54% 10.15% 1.01% 6.23%
EBITDA Q/Q Growth
-50.21% -334.48% 29.72% 22.92% 140.05% -2,669.32% 88.83% 12.75% -54.67% 47.84%
EBIT Q/Q Growth
-97.25% -10,484.09% 32.09% 20.25% 102.31% -33,095.85% 85.58% 13.27% -40.74% 39.36%
NOPAT Q/Q Growth
-97.39% -9,609.60% 32.09% 20.25% 96.97% -25,082.25% 85.58% 13.27% 9.66% 5.53%
Net Income Q/Q Growth
-87.90% -1,892.70% 34.17% 26.87% -16.19% -897.58% 89.69% 34.35% -61.65% 57.87%
EPS Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth
86.73% 59.83% -123.81% 223.14% 5.17% 45.83% -51.34% -41.03% -461.94% 261.31%
Free Cash Flow Firm Q/Q Growth
-2.63% 3.67% 12.65% 73.67% 46.70% 305.33% 115.48% 8.30% -46.68% -169.70%
Invested Capital Q/Q Growth
-0.24% 14.12% -8.23% 4.61% -2.48% -33.11% -2.21% 4.04% 18.11% -5.90%
Profitability Metrics
- - - - - - - - - -
Gross Margin
43.63% 19.18% 28.43% 30.32% 47.05% 35.78% 34.28% 37.30% 37.32% 41.79%
EBITDA Margin
10.58% -38.72% -27.84% -20.93% 6.72% -207.24% -25.31% -20.05% -30.70% -15.07%
Operating Margin
0.33% -53.99% -37.52% -29.18% 0.25% -214.34% -33.80% -26.62% -23.81% -21.17%
EBIT Margin
0.33% -53.99% -37.52% -29.18% 0.54% -214.34% -33.80% -26.62% -37.09% -21.17%
Profit (Net Income) Margin
1.27% -35.56% -23.95% -17.08% -15.90% -190.53% -21.47% -12.80% -20.48% -8.12%
Tax Burden Percent
76.44% 71.95% 75.30% 78.84% -196.30% 92.52% 97.69% 81.06% 79.29% 77.02%
Interest Burden Percent
499.15% 91.55% 84.79% 74.25% 1,497.82% 96.08% 65.02% 59.31% 69.65% 49.81%
Effective Tax Rate
23.56% 0.00% 0.00% 0.00% 296.30% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.78% -70.36% -31.24% -16.06% -0.37% -125.50% -20.91% -15.95% -12.89% -14.81%
ROIC Less NNEP Spread (ROIC-NNEP)
0.66% -70.53% -31.40% -16.31% 1.10% -122.16% -21.07% -16.43% -12.56% -15.41%
Return on Net Nonoperating Assets (RNNOA)
-0.51% 51.28% 23.94% 11.36% -0.77% 87.01% 15.35% 11.77% 8.80% 11.54%
Return on Equity (ROE)
0.27% -19.08% -7.30% -4.70% -1.14% -38.49% -5.56% -4.18% -4.09% -3.26%
Cash Return on Invested Capital (CROIC)
18.43% -14.41% -65.49% -23.35% -21.31% 6.38% -1.52% 0.93% -18.98% -30.51%
Operating Return on Assets (OROA)
0.20% -25.08% -9.63% -6.37% 0.11% -47.30% -7.46% -5.98% -7.95% -4.89%
Return on Assets (ROA)
0.78% -16.52% -6.15% -3.73% -3.30% -42.04% -4.74% -2.88% -4.39% -1.88%
Return on Common Equity (ROCE)
0.27% -19.00% -7.27% -4.68% -1.13% -38.48% -5.56% -4.18% -4.09% -3.27%
Return on Equity Simple (ROE_SIMPLE)
21.12% 0.00% -2.17% -3.98% -5.16% 0.00% -15.33% -15.08% -15.11% 0.00%
Net Operating Profit after Tax (NOPAT)
0.27 -26 -17 -14 -0.42 -106 -15 -13 -12 -11
NOPAT Margin
0.25% -37.79% -26.26% -20.42% -0.50% -150.04% -23.66% -18.63% -16.66% -14.82%
Net Nonoperating Expense Percent (NNEP)
0.12% 0.17% 0.16% 0.25% -1.47% -3.34% 0.16% 0.48% -0.33% 0.60%
Return On Investment Capital (ROIC_SIMPLE)
- -1.98% - - - -9.32% - - - -1.00%
Cost of Revenue to Revenue
56.37% 80.82% 71.57% 69.68% 52.95% 64.22% 65.72% 62.70% 62.68% 58.21%
SG&A Expenses to Revenue
24.86% 42.53% 32.95% 26.52% 20.66% 44.97% 33.32% 30.02% 29.20% 31.94%
R&D to Revenue
7.11% 12.57% 14.78% 14.28% 11.82% 16.95% 17.73% 18.99% 16.42% 15.89%
Operating Expenses to Revenue
43.29% 73.17% 65.95% 59.50% 46.80% 250.12% 68.08% 63.91% 61.12% 62.96%
Earnings before Interest and Taxes (EBIT)
0.35 -37 -25 -20 0.46 -151 -22 -19 -27 -16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
11 -26 -18 -14 5.69 -146 -16 -14 -22 -11
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
0.90 0.69 0.73 0.87 0.64 0.75 0.57 0.52 0.58 0.50
Price to Tangible Book Value (P/TBV)
1.08 0.90 0.95 1.13 0.82 0.88 0.67 0.60 0.67 0.58
Price to Revenue (P/Rev)
1.44 1.42 2.53 3.58 2.79 2.96 2.24 2.02 2.37 1.99
Price to Earnings (P/E)
4.25 6.11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
23.54% 16.36% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.67 0.08 0.12 0.61 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.31 0.06 0.13 0.81 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.63 0.16 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.68 0.20 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.93 0.26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.84 0.14 0.83 4.45 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
5.15 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.02 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-0.77 -0.73 -0.76 -0.70 -0.70 -0.71 -0.73 -0.72 -0.70 -0.75
Leverage Ratio
1.12 1.09 1.10 1.09 1.09 1.09 1.09 1.08 1.08 1.09
Compound Leverage Factor
5.60 1.00 0.93 0.81 16.28 1.05 0.71 0.64 0.75 0.54
Debt to Total Capital
1.57% 1.60% 0.44% 0.36% 0.23% 0.10% 0.04% 0.04% 0.04% 0.04%
Short-Term Debt to Total Capital
1.57% 1.60% 0.44% 0.36% 0.23% 0.10% 0.04% 0.04% 0.04% 0.04%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.33% 0.25% 0.35% 0.28% 0.25% -0.25% -0.29% -0.33% -0.31% -0.36%
Common Equity to Total Capital
98.09% 98.15% 99.21% 99.36% 99.52% 100.14% 100.26% 100.29% 100.28% 100.32%
Debt to EBITDA
0.05 0.10 -0.51 -0.10 -0.05 -0.01 0.00 0.00 0.00 -0.01
Net Debt to EBITDA
-2.28 -3.90 79.84 17.94 16.18 5.01 5.06 5.01 4.31 12.93
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.08 0.15 -0.17 -0.08 -0.05 -0.01 0.00 0.00 0.00 -0.01
Net Debt to NOPAT
-3.39 -6.13 26.03 15.11 15.24 6.33 6.43 6.40 5.57 16.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
7.47 6.16 6.57 8.62 6.40 6.01 4.92 4.60 5.07 4.88
Noncontrolling Interest Sharing Ratio
0.52% 0.42% 0.44% 0.37% 0.29% 0.02% 0.05% -0.01% -0.02% -0.30%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
6.79 7.13 7.09 8.15 8.95 6.96 5.09 5.27 4.41 4.85
Quick Ratio
6.59 6.57 6.69 7.61 8.42 6.51 4.71 4.86 3.65 4.49
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-219 -211 -184 -49 -26 53 115 124 66 -46
Operating Cash Flow to CapEx
398.54% 729.82% -430.66% 81.66% 208.94% 538.90% 191.31% 33.15% -79.54% 662.20%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 -369.82 0.00 0.00 0.00 4,724.34 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 146.29 0.00 0.00 0.00 -1,107.79 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 76.27 0.00 0.00 0.00 -2,500.57 0.00
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.62 0.46 0.26 0.22 0.21 0.22 0.22 0.22 0.21 0.23
Accounts Receivable Turnover
7.14 6.46 3.58 3.66 3.73 5.57 6.01 6.36 5.21 4.72
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
11.31 8.62 4.94 3.54 3.43 3.51 3.47 3.21 2.89 3.00
Accounts Payable Turnover
13.19 11.57 9.69 7.24 12.84 9.61 8.62 8.75 9.96 10.45
Days Sales Outstanding (DSO)
51.14 56.51 101.94 99.81 97.77 65.55 60.68 57.37 70.04 77.36
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
27.67 31.56 37.68 50.42 28.43 37.98 42.33 41.73 36.65 34.92
Cash Conversion Cycle (CCC)
23.46 24.95 64.26 49.39 69.34 27.57 18.36 15.64 33.39 42.44
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
373 425 390 408 398 266 260 271 320 301
Invested Capital Turnover
3.05 1.86 1.19 0.79 0.74 0.84 0.88 0.86 0.77 1.00
Increase / (Decrease) in Invested Capital
220 186 167 35 25 -159 -130 -137 -78 35
Enterprise Value (EV)
249 35 47 248 -60 -13 -226 -274 -160 -267
Market Capitalization
1,154 877 922 1,100 800 857 643 587 658 565
Book Value per Share
$42.19 $43.03 $42.84 $42.41 $42.06 $38.34 $37.96 $37.85 $37.58 $37.05
Tangible Book Value per Share
$35.32 $33.05 $32.95 $32.70 $32.49 $32.77 $32.48 $32.47 $32.32 $31.92
Total Capital
1,302 1,291 1,275 1,268 1,265 1,134 1,127 1,129 1,135 1,130
Total Debt
20 21 5.61 4.56 2.89 1.18 0.41 0.41 0.41 0.41
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-909 -845 -879 -855 -864 -867 -866 -858 -815 -828
Capital Expenditures (CapEx)
5.21 4.55 1.84 12 4.90 2.77 3.80 13 19 3.78
Debt-free, Cash-free Net Working Capital (DFCFNWC)
44 34 -0.09 9.60 24 12 5.28 12 40 23
Debt-free Net Working Capital (DFNWC)
615 560 504 468 491 436 311 324 253 281
Net Working Capital (NWC)
594 540 499 463 488 435 311 323 253 281
Net Nonoperating Expense (NNE)
-1.07 -1.51 -1.53 -2.27 13 29 -1.41 -4.14 2.74 -5.10
Net Nonoperating Obligations (NNO)
-909 -845 -879 -855 -864 -867 -866 -858 -815 -828
Total Depreciation and Amortization (D&A)
11 10 6.40 5.60 5.23 5.00 5.48 4.67 4.59 4.65
Debt-free, Cash-free Net Working Capital to Revenue
5.42% 5.52% -0.03% 3.12% 8.21% 4.10% 1.84% 4.15% 14.36% 8.11%
Debt-free Net Working Capital to Revenue
76.54% 90.54% 138.24% 152.26% 171.54% 150.76% 108.15% 111.37% 91.07% 99.16%
Net Working Capital to Revenue
73.99% 87.20% 136.70% 150.78% 170.54% 150.35% 108.01% 111.23% 90.92% 99.01%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding
30.17M 30.10M 29.54M 29.81M 30.01M 29.78M 29.77M 30.10M 30.42M 30.24M
Adjusted Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding
30.87M 30.96M 29.54M 29.81M 30.01M 29.78M 29.77M 30.10M 30.42M 30.24M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
29.44M 29.52M 29.70M 29.93M 29.63M 29.78M 29.92M 30.30M 30.59M 30.83M
Normalized Net Operating Profit after Tax (NOPAT)
0.35 -26 -17 -14 0.15 -106 -15 -13 -12 -11
Normalized NOPAT Margin
0.33% -37.82% -26.26% -20.42% 0.18% -150.04% -23.66% -18.63% -16.66% -14.82%
Pre Tax Income Margin
1.66% -49.42% -31.81% -21.66% 8.10% -205.94% -21.98% -15.79% -25.83% -10.55%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 6.54 0.00 0.00 0.00 -1,900.57 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 -6.00 0.00 0.00 0.00 -853.95 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 -63.47 0.00 0.00 0.00 -3,293.36 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 -76.02 0.00 0.00 0.00 -2,246.74 0.00
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
16.79% 52.38% -270.48% -127.08% -48.10% -14.30% -14.60% -14.81% -13.43% -0.51%

Frequently Asked Questions About Fulgent Genetics' Financials

When does Fulgent Genetics's financial year end?

According to the most recent income statement we have on file, Fulgent Genetics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Fulgent Genetics' net income changed over the last 2 years?

Fulgent Genetics' net income appears to be on an upward trend, with a most recent value of -$43.82 million in 2024, falling from $141.92 million in 2022. The previous period was -$175.24 million in 2023.

What is Fulgent Genetics's operating income?
Fulgent Genetics's total operating income in 2024 was -$73.92 million, based on the following breakdown:
  • Total Gross Profit: $107.22 million
  • Total Operating Expenses: $181.13 million
How has Fulgent Genetics revenue changed over the last 2 years?

Over the last 2 years, Fulgent Genetics' total revenue changed from $618.97 million in 2022 to $283.47 million in 2024, a change of -54.2%.

How much debt does Fulgent Genetics have?

Fulgent Genetics' total liabilities were at $90.81 million at the end of 2024, a 11.0% decrease from 2023, and a 21.8% decrease since 2022.

How much cash does Fulgent Genetics have?

In the past 2 years, Fulgent Genetics' cash and equivalents has ranged from $55.14 million in 2024 to $97.47 million in 2023, and is currently $55.14 million as of their latest financial filing in 2024.

How has Fulgent Genetics' book value per share changed over the last 2 years?

Over the last 2 years, Fulgent Genetics' book value per share changed from 43.03 in 2022 to 37.05 in 2024, a change of -13.9%.



This page (NASDAQ:FLGT) was last updated on 4/25/2025 by MarketBeat.com Staff
From Our Partners